FDA approves two therapies to treat IBS-D
The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Food and Drug Administration (FDA) | Irritable Bowel Syndrome | Women | Xifaxan